10-Q: Health Catalyst Reports Q2 2026 Results, Faces Revenue Decline

Health Catalyst, Inc. reported a 13% decrease in total revenue for Q2 2026 compared to the prior year, driven by client churn and down-selling related to platform migrations, alongside a significant goodwill impairment charge.

Summary

• Health Catalyst reported a 13% decrease in total revenue for the three months ended June 30, 2026, to $70.5 million, compared to $80.7 million in the same period last year.
• Technology revenue decreased by 8% to $48.8 million, while professional services revenue fell by 22% to $21.7 million.
• Net loss for the quarter was $40.5 million, a slight improvement from $41.0 million in the prior year's quarter.
• However, for the six months ended June 30, 2026, the net loss widened significantly to $151.6 million from $64.7 million in the prior year, largely due to a $122.5 million goodwill impairment charge.
• The company completed the divestiture of its Vitalware Business for $147 million and used the proceeds to repay its Credit Agreement in full.
• Adjusted EBITDA showed a slight increase to $9.9 million for the quarter, but the company expects near-term negative impacts on revenue and margins from the Vitalware divestiture and ongoing platform migrations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant revenue declines, increased net losses, and substantial goodwill impairment charges, despite some operational efficiencies.

Positives

• Completed the divestiture of the Vitalware Business for $147 million.
• Used proceeds from the Vitalware Transaction to fully repay outstanding obligations under the Credit Agreement, significantly reducing interest expense.
• Adjusted EBITDA for the quarter increased slightly to $9.9 million from $9.3 million in the prior year.
• Professional services gross margin improved year-over-year for both the quarter and the six-month period.
• The company has $24.8 million remaining authorization under its share repurchase plan.

Negatives

• Total revenue decreased by 13% to $70.5 million for the three months ended June 30, 2026.
• Technology revenue decreased by 8% and professional services revenue decreased by 22% for the three months ended June 30, 2026.
• Net loss for the six months ended June 30, 2026, increased to $151.6 million from $64.7 million in the prior year.
• Recorded a significant goodwill impairment charge of $122.5 million for the six months ended June 30, 2026.
• Expects near-term negative impacts on total revenue, gross profit, net income, Adjusted Gross Profit, and Adjusted EBITDA due to the Vitalware Transaction.
• Continued client churn and down-selling related to the migration from DOS to Ignite platform is impacting revenue.
• Sales and marketing expenses as a percentage of revenue increased from 16% to 17% for the six-month period.
• General and administrative expenses increased by 15% for the six-month period.

Risks

• Continued macroeconomic challenges, including high inflation, high interest rates, and market volatility, could adversely affect clients and the company's business.
• The company faces intense competition in the healthcare solutions market, and failure to compete effectively could harm results.
• Client churn and down-selling related to the migration from DOS to Ignite platform pose a significant risk to revenue.
• The divestiture of the Vitalware Business is expected to negatively impact future revenue and profitability.
• Reliance on third-party providers for computing infrastructure, such as Microsoft Azure, creates risks of service disruptions.
• Failure to protect intellectual property rights could impair the company's ability to protect its proprietary technology and brand.
• The company's increasing reliance on AI and machine learning technologies exposes it to risks related to development, regulatory uncertainties, and potential third-party claims.
• The company has experienced significant net losses and expects to continue incurring losses, with a risk of not achieving profitability.

Future Outlook

The company expects near-term headwinds to revenue due to the Vitalware Transaction, a reduction in TEMS revenue, and ongoing migrations to Health Catalyst Ignite. Technology gross margin and Adjusted Technology Gross Margin are also expected to decline in the near term due to these factors. The company anticipates being through churn pressure associated with DOS to Ignite migrations by the end of 2027. The repayment of debt is expected to significantly reduce future interest expense.

Management Comments

• We envision a future where all healthcare decisions are data-informed.
• We are focused on margin expansion as part of our transformation to streamline operations and optimize our cost structure.
• Moving forward our focus is building a technology business that wins in the market, operating with efficiency and discipline, and investing in our AI-enabled intelligence that differentiates our solutions.
• The Vitalware Transaction, which is part of Project Nexus, provided us with the ability to fully repay all obligations under our Credit Agreement and we believe gives us flexibility to make targeted investments in our core business.

Industry Context

StockSavvy.ai notes that the healthcare data analytics market is highly competitive, with significant pressure from large EHR vendors and a trend towards consolidation. The company's revenue decline and focus on restructuring initiatives reflect broader industry challenges related to client budget constraints and the complexities of technology migrations.

Legal Proceedings

• No legal proceedings are currently disclosed that management believes would have a material adverse effect on the business.

Related Party Transactions

• Revenue recognized from a client, Carle Health, where a member of its executive leadership team served on the board until July 16, 2026, amounted to $8.4 million for the six months ended June 30, 2026.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances and potential stock price volatility.
• Clients may face disruptions or changes in service offerings due to ongoing platform migrations and the Vitalware divestiture.
• Employees may be impacted by restructuring initiatives, potentially affecting morale and retention.

Next Steps

• Continue to focus on operating efficiency and disciplined investment in AI-enabled intelligence.
• Strengthen and simplify the commercial engine to drive technology ARR bookings.
• Improve client retention through more predictable migrations and clearer value realization.
• Increase efficiency and reduce time to value by eliminating operational complexity and scaling work through automation and global resources.
• Continue to refine the strategic operating plan.
• Expect to generally be through churn pressure associated with DOS to Ignite migrations by the end of 2027.

Key Dates

Recommendation

The significant revenue decline, widening net loss, substantial goodwill impairment, and negative future outlook, despite the debt repayment and divestiture, suggest a challenging operating environment. The ongoing client churn and migration issues, coupled with increased G&A expenses, indicate potential headwinds that could negatively impact future performance and stock valuation.

Keywords

Healthcare Data Analytics, Cloud-based Platform, Software Subscriptions, Professional Services, Healthcare IT, Patient Engagement, Data Management, Clinical Improvement